Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Yothers

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
Journal of the National Cancer Institute|July 4, 2013
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
Cancer|October 22, 2025
Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trialsGillian Gresham, N Lynn Henry, Hanna Bandos, et al.
JAMA Oncology|June 9, 2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical TrialNan Song, Katherine L Pogue-Geile, Patrick G Gavin, et al.
Cancer|May 17, 2022
Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trialsGina Kim, Jessica M Pastoriza, Jiyue Qin, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
Journal of the National Cancer Institute|July 4, 2013
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
Cancer|October 22, 2025
Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trialsGillian Gresham, N Lynn Henry, Hanna Bandos, et al.
JAMA Oncology|June 9, 2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical TrialNan Song, Katherine L Pogue-Geile, Patrick G Gavin, et al.
Cancer|May 17, 2022
Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trialsGina Kim, Jessica M Pastoriza, Jiyue Qin, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Pageof 12